Composition and method for inhibiting amyloid β accumulation and/or aggregation
AssigneeInnopeutics Corporation
InventorsSang Hun Lee, Jae Jin Song, Yun Seon Yang, Tae Gyun Kim
Life of this patent
Estimating the term…
Abstract
Disclosed herein is an amyloid β accumulation and/or aggregation inhibitor. A technique for inhibiting amyloid β accumulation and/or aggregation by concurrently introducing Nurr1 and Foxa2 genes and introducing the co-expression of the genes is also provided. When used, the composition can be applied to the prevention or treatment of a neurodegenerative disease caused by amyloid β accumulation and/or aggregation, such as Alzheimer's disease.
Claims32
A method for inhibiting amyloid β accumulation and/or aggregation in a subject, comprising the steps of:
- identifying a subject in need of treatment for inhibiting amyloid β accumulation;
- and
- administering to the subject a therapeutically effective amount of a composition comprising Nurr1 and Foxa2 genes, wherein the administration inhibits amyloid β accumulation.
A method for treatment of a disease in a subject caused by amyloid β accumulation and/or aggregation, comprising the steps of:
- identifying a subject in need of treatment for a disease caused by amyloid β accumulation;
- and
- administering to the subject a therapeutically effective amount of a composition comprising Nurr1 and Foxa2 genes, wherein the administration treats a disease caused by amyloid β accumulation and/or aggregation in the subject.
A method for inhibiting cellular senescence caused by amyloid β accumulation and/or aggregation in a subject, comprising the steps of:
- identifying a subject in need of treatment for inhibiting cellular senescence caused by amyloid β accumulation and/or aggregation;
- and
- administering to the subject a therapeutically effective amount of a composition comprising a vector carrying Nurr1 and Foxa2 genes, wherein the administration inhibits cellular senescence in the subject.
A method for inhibiting expression of inflammasomes, complements (C1 and C3), chemokines (CCL3 and CCL4), apolipoprotein E (ApoE), nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB), or asparaginyl endopeptidase (AEP) in a subject, comprising the steps of:
- identifying a subject in need of treatment for inhibiting expression of inflammasomes, complements (C1 and C3), chemokines (CCL3 and CCL4), apolipoprotein E (ApoE), nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB), or asparaginyl endopeptidase (AEP);
- and
- administering to the subject a therapeutically effective amount of a composition comprising Nurr1 and Foxa2 genes, wherein the administration inhibits expression of inflammasomes, complements (C1 and C3), chemokines (CCL3 and CCL4), apolipoprotein E (ApoE), nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB), or asparaginyl endopeptidase (AEP) in the subject.
A method for increasing expression of synaptogenic proteins (synapsin1 and synaptophsin) in a subject, comprising the steps of:
- identifying a subject in need of a treatment which increases expression of synaptogenic proteins (synapsin1 and synaptophsin);
- and
- administering to the subject a therapeutically effective amount of a composition comprising Nurr1 and Foxa2 genes, wherein the administration increases expression of synaptogenic proteins (synapsin1 and synaptophsin) in the subject.
Dependencies are inferred from the claim text.